Aurobindo Pharma clocked a 4 per cent decline in consolidated net profit at ₹532 crore in the fourth quarter ended March 31, 2017 compared to ₹554 crore in the corresponding quarter of the previous financial year.
The total revenue of the Hyderabad-based company decreased 2.6 per cent to ₹3,682 crore (₹3,782 crore).
For the year ended March 2017, the company’s net profit grew 13.7 per cent to ₹2,301 crore on a 7.3 per cent increase in total revenue at ₹15,206 crore, over the year ended March 2016.
Commenting on the company’s performance, N Govindarajan, Managing Director, Aurobindo Pharma, said: “We will continue to invest in building a differentiated and speciality product portfolio which will sustain the growth momentum for the future.’’
The board of directors of the company approved second interim dividend of ₹1.25 per equity share of Re 1 for the financial year 2016-17.
The board also decided to roll back its previous decision to transfer its injectable unit to its wholly owned subsidiary, Curepro Parenterals, which has not been implemented in view of the “expansion and growth plans of the company.’’
Aurobindo Pharma’s scrip rose 12.94 per cent to ₹580.15 on the BSE on Tuesday.